Nucl Med Mol Imaging.  2017 Mar;51(1):22-31. 10.1007/s13139-016-0411-3.

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

Affiliations
  • 1Department of Nuclear Medicine, Soonchunhyang University Hospital, Cheonan, South Korea.
  • 2Rheinisch Westfä lische Technische Hochschule Aachen University, Aachen, Germany.
  • 3Department of Radiology, Seoul National University College of Medicine, Seoul, South Korea.
  • 4Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehang-ro, Jongno-gu, Seoul 03080, Republic of Korea. larrycheon@gmail.com

Abstract

The recent advance in hybrid imaging techniques enables offering simultaneous positron emission tomography (PET)/magnetic resonance imaging (MRI) in various clinical fields. ¹â¸F-fluorodeoxyglucose (FDG) PET has been widely used for diagnosis and evaluation of oncologic patients. The growing evidence from research and clinical experiences demonstrated that PET/MRI with FDG can provide comparable or superior diagnostic performance more than conventional radiological imaging such as computed tomography (CT), MRI or PET/CT in various cancers. Combined analysis using structural information and functional/molecular information of tumors can draw additional diagnostic information based on PET/MRI. Further studies including determination of the diagnostic efficacy, optimizing the examination protocol, and analysis of the hybrid imaging results is necessary for extending the FDG PET/MRI application in clinical oncology.

Keyword

FDG; Oncology; PET/MRI; Positron emission tomography/magnetic resonance imaging
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr